Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 6/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.58 |
| ▸ | BLM | P54132 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 4/20 | 0.58 |
| ▸ | RECQL | P46063 | 3/20 | 0.58 |
| ▸ | NSD2 | O96028 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | EGFR | P00533 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.58 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.58 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6665492 | 0.96 | CYP19A1 (0.72) | CYP19A1LMNAMEN1KMT2AMAPK1 | |
| SCHEMBL6661577 | 0.90 | CYP19A1 (0.80) | CYP19A1LMNAMEN1KMT2AMAPK1 | |
| SCHEMBL20885913 | 0.89 | KMT2A (0.60) | CYP19A1LMNAMEN1KMT2AMAPK1 | |
| SCHEMBL6666259 | 0.86 | CYP19A1 (0.73) | CYP19A1LMNAMEN1KMT2AMAPK1 | |
| Amentantrone SCHEMBL30390727 | 0.84 | MEN1 (0.74) | CYP19A1LMNAMEN1KMT2AMAPK1 | |
| Amentantrone SCHEMBL3273264 | 0.84 | MEN1 (0.74) | CYP19A1LMNAMEN1KMT2AMAPK1 | |
| SCHEMBL5161533 | 0.84 | MEN1 (0.55) | CYP19A1LMNAMEN1KMT2AMAPK1 | |
| Amentantrone SCHEMBL29580057 | 0.84 | MEN1 (0.74) | CYP19A1LMNAMEN1KMT2AMAPK1 | |
| SCHEMBL3917115 | 0.83 | NSD2 (0.65) | CYP19A1LMNAMEN1KMT2AMAPK1 | |
| SCHEMBL375450 | 0.82 | TOP2B (0.71) | CYP19A1LMNAMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1087935-B1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INT LTD (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-20030203975-A1 | Anti-cancer agents | BTG INTERNATIONAL LIMITED (GB) | 2003-10-30 | — | — | US | disclosed |
| EP-1087935-A1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INTERNATIONAL LIMITED (GB) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065866-A1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INTERNATIONAL LIMITED (GB) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203975-A1 | Anti-cancer agents | TOP2B, TOP2A, TOP1 | CYP19A1 1005/4885LMNA 3469/4885MEN1 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.